Results 31 to 40 of about 5,946,067 (288)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases

Supportive Care in Cancer, 2021
This study aimed to evaluate the association between clinical characteristics and development of medication-related osteonecrosis of the jaw (MRONJ) in patients who underwent dental examinations before the initiation of treatment with denosumab or ...
H. Ikesue, M. Mouri, H. Tomita, M. Hirabatake, Mai Ikemura, N. Muroi, S. Yamamoto, T. Takenobu, K. Tomii, M. Kawakita, H. Katoh, T. Ishikawa, H. Yasui, T. Hashida   +13 more
semanticscholar   +1 more source

Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

Blood Advances, 2021
An exploratory end point from a recent trial in patients with newly diagnosed multiple myeloma showed that median progression-free survival (PFS) was increased by 10.7 months with denosumab vs zoledronic acid. We performed additional analyses to identify
E. Terpos, N. Raje, P. Croucher, R. García-Sanz, X. Leleu, W. Pasteiner, Yang Wang, A. Glennane, J. Canon, C. Pawlyn   +9 more
semanticscholar   +1 more source

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

New England Journal of Medicine, 2007
D. Black, P. Delmas, R. Eastell, I. Reid, S. Boonen, J. Cauley, F. Cosman, P. Lakatos, P. Leung, Z. Man, C. Mautalen, P. Mesenbrink, Huilin Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T. Hue, D. Sellmeyer, E. Eriksen, S. Cummings   +20 more
semanticscholar   +3 more sources

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases [PDF]

, 2005
PURPOSE: Bone metastases secondary to solid tumors increase the risk of skeletal-related events (SREs), including the occurrence of pathological fracture (PF), radiation to bone (RB), surgery to bone (SB), and spinal cord compression (SCC).
Roger von Moos, Jean-Jacques Body, Blair Egerdie, Alison Stopeck, Janet Brown, Lesley Fallowfield, Donald L. Patrick, Charles Cleeland, Danail Damyanov, Felipe Salvador Palazzo, Gavin Marx, Ying Zhou, Ada Braun, Arun Balakumaran, Yi Qian, RE Coleman, RE Coleman, R Moos von, S Vadhan-Raj, GR Mundy, GD Roodman, JA Ford, A Lipton, F Saad, LS Rosen, L Costa, CS Cleeland, K Lemay, CS Cleeland, M Maltoni, L Costa, CS Cleeland, R Moos von, L Costa, AT Stopeck, K Fizazi, DH Henry, D Henry, GV Scagliotti, A Lipton, CS Cleeland, KC Chung, DF Cella, K Webster, N Sathiakumar, N Sathiakumar, K Fizazi, M Yong, M Norgaard, K Cetin, C Nieder, E Chow, MR Smith, A Hussain, AM Abdulhalim, G Oster   +55 more
core   +5 more sources

Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. [PDF]

PLoS ONE, 2014
Salivary adenoid cystic carcinoma is an epithelial tumor in the head and neck region. Despite its slow growth, patients with salivary adenoid cystic carcinoma exhibit poor long term survival because of a high rate of distant metastasis. Lung and bone are
Xi-Yuan Ge, Lin-Qian Yang, Yang Jiang, Wen-Wen Yang, Jia Fu, Sheng-Lin Li   +5 more
doaj   +1 more source

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Journal of Orthopaedic Surgery and Research, 2021
Objective To compare the efficacy and safety between denosumab and zoledronic acid for advanced cancer with bone metastasis. Methods MEDLINE, EMBASE, and the Cochrane library databases were searched for randomized controlled trials up to December 2020 ...
Lianghai Jiang, Xianghua Cui, Haoning Ma, Xiangsheng Tang   +3 more
semanticscholar   +1 more source

Zoledronic Acid-Loaded Hybrid Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticle: Novel Fabrication and Safety Verification

Frontiers in Bioengineering and Biotechnology, 2021
Osteosarcoma is a malignant tumor that often occurs in adolescents and children. Zoledronic acid, a new-generation bisphosphonate, has been widely used as an antitumor drug to inhibit bone metastasis.
Yan Xu, Zheng Zhang, He-Hui Wang, Wu Zhong, Chengmei Sun, Wei Sun, Hongwei Wu   +6 more
semanticscholar   +1 more source

Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA‐HD Study Extension

Journal of Bone and Mineral Research, 2021
Combined teriparatide and denosumab rapidly and substantially increases bone mineral density (BMD) at all anatomic sites. Discontinuation of denosumab however, results in high‐turnover bone loss and increased fracture risk.
S. Ramchand, Natalie L David, Hang Lee, R. Eastell, J. Tsai, B. Leder   +5 more
semanticscholar   +1 more source

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan

Archives of Osteoporosis, 2021
Summary Among hypothetical cohorts of older osteoporotic women without prior fragility fracture in Japan, we evaluated the cost-effectiveness of two treatment strategies using a simulation model.
Takahiro Mori, C. Crandall, Tomoko Fujii, D. Ganz   +3 more
semanticscholar   +1 more source

Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology

Dental journal, 2021
The aim of this systematic review is to present an up-to-date review of available publications investigating the cellular mechanisms initiating the development of medication-related osteonecrosis of the jaw caused by zoledronic acid.
Ayat Alsalih, A. Dám, P. Lindberg, A. Truedsson   +3 more
semanticscholar   +1 more source